Protocol Ledger

NCT04238715 · Phase II · COMPLETED

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

Interventional Phase II clinical trial protocol NCT04238715 sponsored by Eisai in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-01-22 Enrollment: 63 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04238715
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)63 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04238715
Protocol FieldVerified Registry Value
NCT IdentifierNCT04238715
Consolidated Lead SponsorEisai
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment63 participants (ACTUAL)
Registered Start Date2020-01-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI